This presentation contains "forward-looking statements," including statements regarding the proposed development plans and timelines for the Company's product candidates and the success, cost and timing of its research activities and clinical trials. Forward-looking statements can generally be identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "potential," "seek," "should," "think," "will," "would" and similar expressions, or they may use future dates.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management's expectations are described in greater detail under the heading "Risk Factors" in the Company's quarterly report on Annual Report on Form 20-F and in any subsequent periodic or current report that the Company files with the SEC.
All forward-looking statements reflect the Company's estimates only as of the date of this release (unless another date is indicated) and should not be relied upon as reflecting the Company's views, expectations or beliefs at any date subsequent to the date of this release.
Clinical-stage precision targeting for solid tumors using clonal neoantigen-reactive T cells (cNeT)
Targeting clonal neoantigens: a novel class of cancer target present on all tumor cells
We have developed a proprietary patent protected AI platform (PELEUS®) that is validated on real world patient data (TRACERx) and which can be used to identify personal clonal neoantigens
Controlled precision therapy
Scientific platform that can quantify, characterize and track tumor reactive T cells, target engagement and mechanism of action
Emerging PoC for cNeT in NSCLC
Durable disease control achieved with cNeT monotherapy, 71% (5/7) NSCLC patients (including 1 PR and 4 SDs) with encouraging safety and tolerability
Near-term clinical milestones
Clinical and translational updates in 2023: 15-20 new patients across NSCLC (CHIRON) monotherapy and melanoma (THETIS) monotherapy and in combination with check-point inhibitor (anti-PD-1)
Strong cash position supports all planned operations into mid-2025
Cash runway of $173M (£143M) as of December 31, 2022
Achilles Therapeutics plc published this content on 07 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 March 2023 12:13:04 UTC.
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.
ACHILLES THERAPEUTICS PLC 
